title: Adverse effects of vigabatrin in Angelman syndrome.
abstract: New antiepileptic drugs designed for enhancing GABAergic inhibition, such as vigabatrin (VGB) may be effective in Angelman syndrome (AS), because associated convulsions could be related to a reduced GABA-receptor density or receptor abnormality. From our preliminary experiences in four children with AS treated with VGB, we conclude that it may induce and increase seizures in patients with AS.
authors.affiliation: Department of Pediatric Neurology, University Children's Hospital, Zurich, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Kuenzle
authors.forename: M
authors.initials: M
authors.lastname: Steinlin
authors.forename: G
authors.initials: G
authors.lastname: Wohlrab
authors.forename: E
authors.initials: E
authors.lastname: Boltshauser
authors.forename: B
authors.initials: B
authors.lastname: Schmitt
mesh_terms: D000328:Adult; D017204:Angelman Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics; D000927:Anticonvulsants / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D004827:Epilepsy / Q000139:chemically induced* / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D018079:Receptors, GABA / Q000187:drug effects / Q000235:genetics; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000927:Anticonvulsants; D018079:Receptors, GABA; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin